Abstract 147: Elevated Serum Resistin Levels are Associated with Angiographically Significant Coronary Artery Disease: A Meta-analysis.

Abstract

Background: Resistin is a novel inflammatory cytokine secreted primarily by mononuclear inflammatory cells and adipocytes. It upregulates the expression of vascular adhesion molecules and stimulates smooth muscle cell proliferation, thereby contributing to atherogenesis in the vascular wall. We conducted a meta-analysis to evaluate the association between serum resistin levels and presence of angiographically significant coronary artery disease (CAD) in patients undergoing diagnostic coronary angiography (DCA). Methods: We searched MEDLINE, CINAHL and COCHRANE databases for studies reporting serum resistin levels in the patients with history of angina or positive stress test undergoing DCA. Patients with coronary stenosis > 50% in at least 1 coronary artery were considered to have significant CAD. They were included in the study group, and rest were included in control group. A calculation of weighted standardized mean difference (SMD) in serum resistin level between the CAD and control groups was conducted. Results: A literature search yielded 158 articles, but only 11 studies enrolling 3291 patients were included in the meta-analysis. The median age and body mass index (BMI) of the CAD group was 63 yrs (IQR 61-65) and 27 kg/m2 (IQR 25-29) versus 59 yrs (IQR 57-61) and 28 kg/m2 (IQR 26-29) in the control group. There were more females in the control group 48% (IQR 46-58) versus 27% (IQR 24-33) in CAD group. The unweighted median serum resistin levels in the CAD group were 5.7 ng/ml (IQR 4.1-16.1) vs 4.3 ng/ml (IQR 3.1-8.2) in the control group. The SMD of serum resistin level was 0.38 (95% CI 0.18- 0.57), P<0.001 comparing those in the CAD group and control group. None of the covariates (age, BMI and sex) accounted for statistical significance. Conclusion: An elevated serum resistin level is independently associated with the presence of angiographically significant CAD. Serum resistin levels can potentially be used as a biomarker for cardiac risk stratification.